Get the Stockscreener App
1.28
14.29%
0.16
Phio Pharmaceuticals Corp stock is traded at $1.28, with a volume of 14.65M.
It is up +14.29% in the last 24 hours and up +10.34% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
See More
Previous Close:
$1.12
Open:
$1.29
24h Volume:
14.65M
Relative Volume:
4.80
Market Cap:
$13.67M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.1569
EPS:
-8.156
Net Cash Flow:
$-11.09M
1W Performance:
+38.38%
1M Performance:
+10.34%
6M Performance:
-39.91%
1Y Performance:
-28.09%
1-Day Range:
$1.19
$1.44
1-Week Range:
$0.8127
$1.48
52-Week Range:
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.2701 | 12.06M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.46 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
777.81 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
832.27 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.00 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.04 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
DealFlow Events Sets Stage for PEIO Stock Momentum - StocksToTrade
Phio Pharmaceuticals (PHIO) stock rises premarket as new PH-762 skin cancer data keeps traders circling - TechStock²
Phio reports positive results from PH-762 skin cancer trial By Investing.com - Investing.com Nigeria
PHIO: HC Wainwright & Co. Reiterates Buy Rating with $14 Price Target | PHIO Stock News - GuruFocus
Phio Pharmaceuticals Corp. (PHIO) stock: jumps 43% as cancer trial shows strong safety and response rates - parameter.io
Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients - Benzinga
DealFlow Conference Set to Boost Over 100 Companies - StocksToTrade
Phio Pharmaceuticals stock soars after strong cancer treatment results By Investing.com - Investing.com South Africa
Phio Pharmaceuticals stock soars after strong cancer treatment results - Investing.com
DealFlow Discovery Conference Unveils Corporate Opportunities - timothysykes.com
Phio Pharmaceuticals Reports Positive PH-762 Phase 1b Safety Results - TipRanks
Phio Pharmaceuticals Corp Announces Positive Phase 1b Trial Results for PH-762 - TradingView
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial - TMX Newsfile
Retail Surge: Does Phio Pharmaceuticals Corp offer margin of safety2025 Growth vs Value & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Can Phio Pharmaceuticals Corp. sustain its profitability2025 Momentum Check & Long-Term Growth Portfolio Plans - mfd.ru
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference - TMX Newsfile
Cancer drug developer Phio joins free Atlantic City investor discovery event - stocktitan.net
Aug PreEarnings: Is Hennessy Capital Investment Corp VII stock a top performer YTDJuly 2025 Macro Moves & Consistent Return Investment Signals - baoquankhu1.vn
Phio Pharmaceuticals reports 70% response rate in skin cancer trial By Investing.com - Investing.com India
Phio Reports Positive Phase 1b PH-762 Skin Cancer Data - TipRanks
Phio Pharmaceuticals Corp Announces Key Tumor Response Data from PH-762 Trial - TradingView
Phio Pharmaceuticals reports 70% response rate in skin cancer trial - Investing.com
Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial - TMX Newsfile
Is Phio Pharmaceuticals Corp. stock a contrarian buyLong-Term Growth Stocks & Low Risk Trading Plans - Bollywood Helpline
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - TMX Newsfile
Retail Trends: Does Phio Pharmaceuticals Corp offer margin of safetyJuly 2025 Review & Community Trade Idea Sharing Platform - baoquankhu1.vn
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026 - TMX Newsfile
Cancer gene-silencing update from Phio at Sidoti virtual conference - Stock Titan
Pullback Watch: How does Phoenix Laser Systems Inc Preferred Security score in quality rankingsBreakout Watch & Fast Gain Swing Alerts - baoquankhu1.vn
Guidance Update: What is the next catalyst for Phio Pharmaceuticals Corp2025 Investor Takeaways & Expert Curated Trade Setups - baoquankhu1.vn
Aug Big Picture: Can Phio Pharmaceuticals Corp stock rebound after recent weaknessWeekly Volume Report & Trade Opportunity Analysis - Bộ Nội Vụ
Market Overview: Is Phio Pharmaceuticals Corp a stock for growth or value investorsMarket Sentiment Review & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Trend Recap: How Phio Pharmaceuticals Corp stock reacts to Fed rate cutsQuarterly Performance Summary & High Win Rate Trade Tips - Bộ Nội Vụ
Why Phio Pharmaceuticals Corp. stock is a value investor pickShort Setup & Free Weekly Chart Analysis and Trade Guides - Улправда
Will Phio Pharmaceuticals Corp. stock benefit from infrastructure spendingJuly 2025 Setups & Safe Entry Trade Signal Reports - Улправда
Why retail investors pile into Phio Pharmaceuticals Corp. stock2026 world cup usa national team semifinals defensive leaders low block defense odds analysis insights - Улправда
Insider Buying: Robert Bitterman Acquires Additional Shares of P - GuruFocus
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Momentum Shift: Can Phio Pharmaceuticals Corp stock beat analyst upgradesBuy Signal & Reliable Breakout Forecasts - moha.gov.vn
Best Value Stocks to Buy for April 23rd - MSN
Phio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s Elated - MSN
Phio Pharmaceuticals chairman Bitterman buys $5,100 in stock By Investing.com - Investing.com South Africa
Phio Pharmaceuticals chairman Bitterman buys $5,100 in stock - Investing.com
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series - TMX Newsfile
MSN Money - MSN
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - TMX Newsfile
Phio To Commence A Toxicology Study For PH-762; Initiatives Underway For A Viable Product In 2026 - Nasdaq
Phio to begin FDA-required toxicology study for cancer drug PH-762 - Investing.com Nigeria
Phio Advances PH-762 With FDA-Backed Toxicology Study - TipRanks
Phio to begin FDA-required toxicology study for cancer drug PH-762 By Investing.com - Investing.com South Africa
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phio Pharmaceuticals Corp Stock (PHIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 23 '25 |
Buy |
1.02 |
5,000 |
5,100 |
286,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 21 '25 |
Buy |
1.14 |
5,000 |
5,700 |
281,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 18 '25 |
Buy |
1.27 |
5,000 |
6,350 |
276,421 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 10 '25 |
Buy |
2.42 |
2,000 |
4,840 |
27,149 |
| Ferrara Robert L | Director |
Jun 10 '25 |
Buy |
2.42 |
2,500 |
6,050 |
15,666 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 09 '25 |
Buy |
2.75 |
1,500 |
4,125 |
25,149 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 21 '25 |
Buy |
1.77 |
3,000 |
5,310 |
22,449 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 22 '25 |
Buy |
1.78 |
1,200 |
2,136 |
23,649 |
| Ferrara Robert L | Director |
May 20 '25 |
Buy |
1.82 |
2,500 |
4,550 |
13,166 |
2.46%
1.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):